Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer

BACKGROUND: Enzalutamide, as a second-generation endocrine therapy drug for prostate cancer (PCa), is prominent representative among the synthetic androgen receptor antagonists. Currently, there is lack of enzalutamide-induced signature (ENZ-sig) for predicting progression and relapse-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yuanfa, Deng, Yulin, Tang, Zhenfeng, Cai, Shanghua, Li, Jinchuang, Liu, Ren, Wan, Jiaming, He, Huichan, Zeng, Guohua, Ye, Jianheng, Han, Zhaodong, Zhong, Weide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060954/
https://www.ncbi.nlm.nih.gov/pubmed/37008945
http://dx.doi.org/10.3389/fendo.2023.1148898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060954/
https://www.ncbi.nlm.nih.gov/pubmed/37008945
http://dx.doi.org/10.3389/fendo.2023.1148898

Ejemplares similares